Effects of Message Content on Intention to Quit Smoking
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02138032|
Recruitment Status : Terminated (Student study which ended at the end of their course.)
First Posted : May 14, 2014
Last Update Posted : December 8, 2014
|Condition or disease||Intervention/treatment||Phase|
|Peripheral Artery Disease||Behavioral: Gains Framed Message Behavioral: Loss Framed Message||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Care Provider)|
|Official Title:||Effects of Message Content on Intention to Quit Smoking in Smokers With Peripheral Artery Disease - a Randomised Controlled Trial|
|Study Start Date :||May 2014|
|Actual Primary Completion Date :||August 2014|
|Actual Study Completion Date :||August 2014|
Experimental: Gains Framed Message
gains framed visual fridge magnet and information sheet about smoking cessation (benefits of quitting smoking)
|Behavioral: Gains Framed Message|
Experimental: Loss Framed Message
loss framed visual fridge magnet and information sheet about smoking cessation (losses of continued smoking)
|Behavioral: Loss Framed Message|
- Intention to quit smoking [ Time Frame: up to 3 weeks ]Intention to quit smoking will be assessed by measuring the strength of the individual's intention with a mean score being calculated from the 3 questions asked. This will generate a score between 1 and 7 with a higher score indicating a higher intention to quit smoking. This measure has been used and reviewed in previous research (Francis et al, 2004).
- Stage of Change - smoking cessation [ Time Frame: baseline and 3 weeks ]Secondly, the Stage of Change (SOC) of intention will be measured, with higher scores indicating a greater intention to quit smoking. The corresponding scores will identify the SOC (1 =pre-contemplation, 2 = contemplation, 3 = preparation, 4 = action). This measure has been adapted from a previous study which investigated stages of change in relation to smoking cessation (Fathelrahman et al. 2009).
- Nicotine Dependence [ Time Frame: Baseline and 3 weeks ]Nicotine dependency will be measured using the standardised Fagerstrom Test for Nicotine Dependence (FTNP: Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991)
- Outcome expectancy beliefs [ Time Frame: Baseline and 3 weeks ]Expectancy beliefs will be measured using a 10-item questionnaire which has been adapted from the Health Action Process Approach (HAPA) assessment tools (Schwarzer, 2007) by making the questions relevant to the specific patient group. The questionnaire is comprised of two sub-scales: positive outcome expectancies (items 1, 3, 4, 6, 9) and negative outcome expectancies (items 2, 5, 7, 8, 10). Each subscale sum scores will range from 5-20.
- Self efficacy [ Time Frame: Baseline and 3 weeks ]Self-efficacy to quit smoking will be measured using a 10-item scale which has been previously used in a study investigating self-efficacy influences on the effects of framing in smoking cessation (Riet, Ruiter, Werrij, & de Vries, 2008). Sum scores will range from 10 to 70 with higher scores indicating greater self-efficacy to quit smoking.
- Risk Perception [ Time Frame: baseline and 3 weeks ]Risk perception of smoking will be measured using a 5-item questionnaire. The items are similar to that used in a previous study (Clarke and Aish, 2002), however the questions have been adapted to increase the relevance for vascular arterial patients. Sum scores will range from 5-35 with higher scores indicating a greater risk perception in regards to smoking.
- Health locus of control [ Time Frame: baseline and 3 weeks ]Health locus of control will be measured using the Multidimensional Health Locus of Control Scale - Form C (MHLC; Wallston, Stein & Smith, 1994).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02138032
|Forth Valley Royal Hospital|
|Larbert, Falkirk, United Kingdom, FK5 4WR|